An influential Republican congressman on Monday cautioned against amending federal spending legislation to rebuke six drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.
During a July 26 U.S. House Rules Committee hearing, Rep. Michael Burgess (R-Texas) cited the drug companies’ lawsuits challenging U.S. Health Resources and Services Administration (HRSA) findings that the firms’ contract pharmacy actions are unlawful in opposing Reps. Abigail Spanberger (D-Va.) and David McKinley’s (R-W.Va.) 340B-related amendment.
An influential Republican congressman on Monday cautioned against amending federal spending legislation to rebuke six drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
